FDA Had Already Warned Telehealth Startup MEDVi Over Misbranded GLP-1 Drugs
MEDVi, a $1.8B AI-powered telehealth company with just two full-time employees, received an FDA warning letter in February 2026 for misbranding compounded semaglutide and tirzepatide.